Drug Trial Radar · NCT05807490
A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Jul 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Apr 5, 2023
Primary completion
Jul 10, 2024
Study completion Jul 10, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study has two parts: Part A and Part B. The purpose of Part A of this study is to learn about the safety, tolerability, and how PF-07328948 is processed by the body when multiple doses of PF-07328948 are given to healthy participants. The purpose of Part B of this study is to understand the amount of PF-07328948 that would be available in the body after taking a single pill. The amount will be compared to the amount of PF-07328948 in a suspension in healthy adults. Part B will be conducted if the results of Part A support further study of PF-07328948. The study is seeking participants who: * are females who are not able to give birth to a child of 18 years of age or older. * are males of 18 years of age or older. * have a BMI of 20.0 to 35.0 kg/m2. * have total body weight of more than 50 kg (110 lbs). Participants in Part A will be randomly selected to receive either PF-07328948 or placebo (a pill that has no medicine in it). Participants in Part B will receive PF-07328948 as suspension and tablet form, both taken by mouth after food or during fasting. For a given participant in Part A, the total study is going to last up to about 12 weeks. This includes from the time of selection till the last follow-up phone call. The participants will be selected if they are fit for the study 28 days before the first dose of the study medicines. Participants who are selected will be admitted to the study site on Day -2 for around 19 days. Following discharge, participants will return for an on-site follow-up visit 7 to 10 days after receiving the final dose of the study medicine. The follow-up contact may be via a telephone call and will happen 28 to 35 days after the final dose of study medicine is given. For a given participant in Part B, the total study is going to last up to about 10-12 weeks. Participants will stay overnight at the CRU for 23 days (Sequence 1) or 18 days (Sequence 2), starting with check-in. In Sequence 1, there will be a minimum of 10 days between doses in Period 1 and 2, and at least 7 days between doses in Period 2 and Period 3. In Sequence 2, there will be a minimum of 7 days between each dose.
Conditions
- Healthy
Interventions
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions BID over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every QD over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions QD over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions QD over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions QD over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948Drug
Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
PF-07328948Drug
PF-07328948 will be administered as oral suspensions QD over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PlaceboDrug
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948Drug
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Time frame: Baseline up to 35 days after last dose of study intervention (approximately 11 weeks)
- Part A: Number of Participants With Clinical Laboratory AbnormalitiesTime frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).
- Part A: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)
- Part A: Number of Participants With Change From Baseline in Electrocardiogram (ECG) FindingsTime frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)
- Part A: Number of Participants With Change From Baseline in Physical Examination FindingsTime frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)
- Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By TelemetryTime frame: 0 to 8 hours post-dose on Day 1
- Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By TelemetryTime frame: 0 to 8 hours post-dose on Day 14
- Part B: Maximum Observed Plasma Concentration (Cmax) of PF-07328948 Tablet Formation and Oral SuspensionTime frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1
- Part B: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07328948 Tablet Formation and Oral SuspensionTime frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1
- Part B: Area Under the Plasma Concentration-time Curve from Time 0 to Extrapolated Infinite Time (AUCinf) of PF-07328948 Tablet Formation and Oral SuspensionTime frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
New Haven Clinical Research Unit
New Haven, Connecticut
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.